Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more

Recent & Breaking News (NDAQ:REPL)

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire May 23, 2024

Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update

GlobeNewswire May 16, 2024

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

GlobeNewswire April 7, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 4, 2024

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

GlobeNewswire March 26, 2024

Replimune to Present at the American Association for Cancer Research Annual Meeting 2024

GlobeNewswire March 6, 2024

Replimune to Present at Three Upcoming Investor Conferences

GlobeNewswire March 5, 2024

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire February 8, 2024

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

PR Newswire January 16, 2024

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 28, 2023

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

GlobeNewswire December 5, 2023

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

GlobeNewswire November 8, 2023

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2023

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire November 3, 2023

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 19, 2023

Replimune Announces Appointment of Emily Hill as Chief Financial Officer

GlobeNewswire September 19, 2023

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire August 3, 2023

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire August 1, 2023

Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma

Business Wire July 31, 2023

Replimune Announces Sander Slootweg will Depart from its Board of Directors

GlobeNewswire July 20, 2023